Filing Details
- Accession Number:
- 0001735276-24-000002
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-02-05 16:05:23
- Reporting Period:
- 2024-02-01
- Accepted Time:
- 2024-02-05 16:05:23
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1178670 | Alnylam Pharmaceuticals Inc. | ALNY | Pharmaceutical Preparations (2834) | 770602661 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1708764 | Lall Indrani Franchini | 675 West Kendall Street Henri A. Termeer Square Cambridge MA 02142 | Evp, Clo & Secretary | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-02-01 | 5,175 | $0.00 | 5,175 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-02-02 | 502 | $170.01 | 4,673 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-02-02 | 820 | $171.14 | 3,853 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-02-02 | 269 | $172.38 | 3,584 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Units | Disposition | 2024-02-01 | 5,175 | $0.00 | 5,175 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 5,175 | No | 4 | M | Direct |
Footnotes
- Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.
- The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $169.57 to $170.57. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $170.58 to $171.54. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $171.80 to $172.60. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- Each restricted stock unit represents a contingent right to receive one share of ALNY common stock.
- On February 1, 2022 the reporting person received 15,525 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 1, 2024, the second tranche of restricted stock units from the February 1, 2022 grant vested and was released, as reported on this Form 4.
Billionaire Hedge Funds
